The Open Surgical Oncology Journal
(Discontinued)
ISSN: 1876-5041 ― Volume 5, 2014
Cytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin: Results of a Transdisciplinary National Survey
The Open Surgical Oncology Journal, 2013, 4: 1-4
Angela W. Chan, Gitonga Munene, Joel Weaver, Anthony MacLean, Jay Easaw, Gilaad G. Kaplan, Robyn D. Parker, Elijah Dixon
Foothills Medical Centre, 1403 – 29th Street NW, Calgary, Alberta, T2N 2T9, Canada
Electronic publication date 23/August/2013
[DOI: 10.2174/1876504120130806001]
Abstract:
Many patients are not referred to centers specializing in the treatment of peritoneal malignancies. This survey evaluates Canadian physician attitudes toward the role of cytoreduction in treating colorectal carcinomatosis.
A discrete-choice questionnaire containing a hypothetical scenario surveyed physician preferences for the management of colorectal carcinomatosis.
Three mail-outs yielded a 49% response rate (217 responses). For synchronous colorectal carcinomatosis, 28.6% favoured cytoreduction with or without HIPEC plus systemic chemotherapy, and 18.9% cytoreduction with HIPEC alone. For metachronous carcinomatosis, 27.4% favoured cytoreduction with or without HIPEC plus systemic chemotherapy, and 14.9% cytoreduction with HIPEC alone. For metachronous carcinomatosis with a single liver metastasis, 24.6% favoured cytoreduction with or without HIPEC plus systemic chemotherapy, and 4.6% cytoreduction with HIPEC alone.
Most physicians do not favor cytoreduction in the treatment of colorectal carcinomatosis. Knowledge translation strategies are needed to improve awareness regarding its utility in specific clinical scenarios.